JP2020533415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533415A5 JP2020533415A5 JP2020536720A JP2020536720A JP2020533415A5 JP 2020533415 A5 JP2020533415 A5 JP 2020533415A5 JP 2020536720 A JP2020536720 A JP 2020536720A JP 2020536720 A JP2020536720 A JP 2020536720A JP 2020533415 A5 JP2020533415 A5 JP 2020533415A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- acceptable salt
- antidepressants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 9
- 239000000935 antidepressant agent Substances 0.000 claims 6
- 229940005513 antidepressants Drugs 0.000 claims 6
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 claims 4
- 239000002269 analeptic agent Substances 0.000 claims 4
- 201000003631 narcolepsy Diseases 0.000 claims 4
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229950004346 gaboxadol Drugs 0.000 claims 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 2
- 206010041349 Somnolence Diseases 0.000 claims 2
- 229940025084 amphetamine Drugs 0.000 claims 2
- 230000037007 arousal Effects 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- 230000003291 dopaminomimetic effect Effects 0.000 claims 2
- -1 fendimethrazine Chemical compound 0.000 claims 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical group C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims 1
- 208000001573 Cataplexy Diseases 0.000 claims 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 1
- 208000004547 Hallucinations Diseases 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 1
- 206010062519 Poor quality sleep Diseases 0.000 claims 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 208000005439 Sleep paralysis Diseases 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 208000003443 Unconsciousness Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- VWYANPOOORUCFJ-UHFFFAOYSA-N alpha-Fernenol Chemical compound CC1(C)C(O)CCC2(C)C3=CCC4(C)C5CCC(C(C)C)C5(C)CCC4(C)C3CCC21 VWYANPOOORUCFJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004823 armodafinil Drugs 0.000 claims 1
- YFGHCGITMMYXAQ-LJQANCHMSA-N armodafinil Chemical compound C=1C=CC=CC=1C([S@](=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-LJQANCHMSA-N 0.000 claims 1
- 229960002430 atomoxetine Drugs 0.000 claims 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims 1
- 229960000794 baclofen Drugs 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 claims 1
- 229960002837 benzphetamine Drugs 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 1
- 229960004890 diethylpropion Drugs 0.000 claims 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002179 ephedrine Drugs 0.000 claims 1
- 229960001451 lisdexamfetamine Drugs 0.000 claims 1
- VOBHXZCDAVEXEY-JSGCOSHPSA-N lisdexamfetamine Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 VOBHXZCDAVEXEY-JSGCOSHPSA-N 0.000 claims 1
- 229960001252 methamphetamine Drugs 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 229960001344 methylphenidate Drugs 0.000 claims 1
- 229960001165 modafinil Drugs 0.000 claims 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 1
- 230000000422 nocturnal effect Effects 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- DAFOCGYVTAOKAJ-UHFFFAOYSA-N phenibut Chemical compound OC(=O)CC(CN)C1=CC=CC=C1 DAFOCGYVTAOKAJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004122 phenibut Drugs 0.000 claims 1
- 229960003562 phentermine Drugs 0.000 claims 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 claims 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 1
- 229960003928 sodium oxybate Drugs 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762557412P | 2017-09-12 | 2017-09-12 | |
| US62/557,412 | 2017-09-12 | ||
| PCT/US2018/050339 WO2019055369A1 (en) | 2017-09-12 | 2018-09-11 | USE OF GABOXADOL IN THE TREATMENT OF NARCOLEPSIA |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533415A JP2020533415A (ja) | 2020-11-19 |
| JP2020533415A5 true JP2020533415A5 (enExample) | 2021-10-21 |
Family
ID=65630168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020536720A Pending JP2020533415A (ja) | 2017-09-12 | 2018-09-11 | ナルコレプシーの処置におけるガボキサドールの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190076409A1 (enExample) |
| EP (1) | EP3661507A4 (enExample) |
| JP (1) | JP2020533415A (enExample) |
| KR (1) | KR20200053570A (enExample) |
| CN (1) | CN111328282A (enExample) |
| AU (1) | AU2018331326A1 (enExample) |
| CA (1) | CA3075478A1 (enExample) |
| IL (1) | IL272962A (enExample) |
| MX (1) | MX2020002741A (enExample) |
| WO (1) | WO2019055369A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3661507A4 (en) * | 2017-09-12 | 2020-11-18 | Ovid Therapeutics Inc. | USE OF GABOXADOL TO TREAT NARCOLEPSIA |
| MX2021005992A (es) | 2018-11-21 | 2021-09-14 | Certego Therapeutics Inc | Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. |
| MX2021016006A (es) | 2019-06-28 | 2022-04-07 | Univ Copenhagen | Tratamiento de trastornos del sistema nervioso central (snc) con perturbaciones del sueño. |
| IL298334A (en) | 2020-05-20 | 2023-01-01 | Certego Therapeutics Inc | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| US20250375429A1 (en) | 2024-05-29 | 2025-12-11 | Smarter Not Harder, Inc. | Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200528098A (en) * | 2003-12-18 | 2005-09-01 | Lundbeck & Co As H | Treatment of insomnia in human patients |
| US20050215521A1 (en) * | 2003-12-22 | 2005-09-29 | Karim Lalji | Modafinil combination therapy for improving sleep quality |
| US9480695B2 (en) * | 2011-09-29 | 2016-11-01 | The University Of Tokyo | Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder |
| US9050302B2 (en) * | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| BR112015022197B1 (pt) * | 2013-03-13 | 2022-06-07 | Sk Biopharmaceuticals Co., Ltd. | Uso de um composto para o tratamento de cataplexia |
| US9682069B2 (en) * | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| WO2017205606A1 (en) * | 2016-05-26 | 2017-11-30 | Ovid Therapeutics Inc. | Methods of treating behavioral syndromes using pipradrol |
| EP3661507A4 (en) * | 2017-09-12 | 2020-11-18 | Ovid Therapeutics Inc. | USE OF GABOXADOL TO TREAT NARCOLEPSIA |
-
2018
- 2018-09-11 EP EP18856943.8A patent/EP3661507A4/en not_active Withdrawn
- 2018-09-11 MX MX2020002741A patent/MX2020002741A/es unknown
- 2018-09-11 JP JP2020536720A patent/JP2020533415A/ja active Pending
- 2018-09-11 KR KR1020207010674A patent/KR20200053570A/ko not_active Withdrawn
- 2018-09-11 CN CN201880072667.9A patent/CN111328282A/zh active Pending
- 2018-09-11 CA CA3075478A patent/CA3075478A1/en active Pending
- 2018-09-11 WO PCT/US2018/050339 patent/WO2019055369A1/en not_active Ceased
- 2018-09-11 AU AU2018331326A patent/AU2018331326A1/en not_active Abandoned
- 2018-09-11 US US16/127,375 patent/US20190076409A1/en not_active Abandoned
-
2020
- 2020-02-27 IL IL272962A patent/IL272962A/en unknown
- 2020-03-25 US US16/829,423 patent/US20200222372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533415A5 (enExample) | ||
| Stiskal et al. | Neonatal paroxetine withdrawal syndrome | |
| CA2126305C (en) | New treatments using venlafaxine | |
| JP2004307506A5 (enExample) | ||
| AU2010211491B2 (en) | Medical use of 5-benzylaminosalicylic acid derivative or its salt | |
| JP2023143940A5 (enExample) | ||
| JP2016506933A5 (enExample) | ||
| RU2020125170A (ru) | Композиции и способы улучшения биодоступности 5-гидрокситриптофана | |
| JP2007505095A (ja) | うつ病及び不安障害の治療のためのアルファ−２−デルタリガンド及びｓｓｒｉ及び／又はｓｎｒｉを含む組み合わせ | |
| RU2012152922A (ru) | Лечение психологических состояний с применением антагонистов м1-мускариновых рецепторов | |
| JP2015534563A5 (enExample) | ||
| JP2012036212A5 (enExample) | ||
| TW200835477A (en) | Methods for treating depression | |
| JP2009542819A5 (enExample) | ||
| TW200800148A (en) | Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient | |
| JP2009542820A5 (enExample) | ||
| CA2525524C (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| JP2011516604A (ja) | 鬱病患者の自殺行動の予防治療のためのミルナシプラン塩酸塩の（１ｓ，２ｒ）鏡像異性体の使用 | |
| JPWO2019148087A5 (enExample) | ||
| RU2019123563A (ru) | Новые комбинации антагонистов н3-рецепторов и ингибиторов обратного захвата норадреналина и их терапевтическое применение | |
| MX2009001219A (es) | Composicion farmaceutica que contiene en combinacion saredutant y un inhibidor selectivo de recaptacion de serotonina o un inhibidor de recaptacion de serotonina/norepinefrina. | |
| Vasile et al. | P. 2. c. 002 Agomelatine versus selective serotoninergic reuptake inhibitors in major depressive disorder and comorbid diabetes mellitus | |
| Shao et al. | Discovery of N-methyl-1-(1-phenylcyclohexyl) methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor | |
| RS51659B (sr) | Upotreba agomelatina za dobijanje lekova namenjenih tretmanu bipolarnih poremećaja | |
| RU2009101143A (ru) | Лечение психологических состояний с применением антаггонистов m1-мускариновых рецепторов |